https://www.selleckchem.com/pr....oducts/ulixertinib-b
Risk of adverse effects, as NNH for most-frequently reported effects, among SGAs versus placebo was 5 [4-6] overall, and highest with quetiapine (NNH = 3), lowest with brexpiprazole (19), 5 (4-6) for esketamine, and 9 (5-106) with lithium. The risk/benefit ratio (NNH/NNT) was 1.80 (1.25-10.6 for lithium and much less favorable for esketamine (0.71 [0.60-0.80]) or SGAs (0.45 [0.17-0.77]). Several modern antipsychotics and esketamine appeared to be useful adjuncts to antidepressants for acute major depressive episo
Like
Comment
Share
